Literature DB >> 15307008

Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV.

Ingrid V Bassett1, Kenneth A Freedberg, Rochelle P Walensky.   

Abstract

Thousands of health care workers are potentially exposed to human immunodeficiency virus (HIV) each year via occupationally acquired needlesticks. The Centers for Disease Control and Prevention (Atlanta, GA) advise health care workers who experience a high-risk occupational exposure from an HIV-infected patient to begin receiving multidrug antiretroviral postexposure prophylaxis (PEP) as soon as possible, preferably within 36 h after exposure. Although the need to prescribe antiretroviral postexposure prophylaxis in a timely fashion is common, few data exist regarding the efficacy and optimal regimen for prophylaxis to prevent transmission. Our objectives were to examine the limited human and animal data on postexposure prophylaxis, to elucidate the factors that affect the choice of 2 versus 3 drugs as the optimal prophylactic drug regimen, and to place these findings within a mathematical framework to help guide the prescription of PEP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307008     DOI: 10.1086/422459

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

Review 2.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  Post-exposure Prophylaxis : What Every Health Care Worker Should Know.

Authors:  K Kapila; R M Gupta; G S Chopra
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Authors:  Kenneth H Mayer; Daniel Jones; Catherine Oldenburg; Sachin Jain; Marcy Gelman; Shayne Zaslow; Chris Grasso; Matthew J Mimiaga
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

5.  A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV.

Authors:  Michelle E Roland; Torsten B Neilands; Melissa R Krone; Thomas J Coates; Karena Franses; Margaret A Chesney; James S Kahn; Jeffrey N Martin
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

Review 6.  Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.

Authors:  Sachin Jain; Kenneth H Mayer
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

Review 7.  What do mathematical models tell us about the emergence and spread of drug-resistant HIV?

Authors:  Rebecca F Baggaley; Kimberly A Powers; Marie-Claude Boily
Journal:  Curr Opin HIV AIDS       Date:  2011-03       Impact factor: 4.283

Review 8.  Chemoprophylaxis for HIV prevention: new opportunities and new questions.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

9.  Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis.

Authors:  Cynthia L Gay; Myron S Cohen
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

10.  "It's Like Plan B but for HIV!" Design and Evaluation of a Media Campaign to Drive Demand for PEP.

Authors:  Jeremy Fagan; Victoria Frye; Rose Calixte; Sachin Jain; Lovely Molla; Adeola Lawal; Marcus P Mosley; Emily Greene; Kenneth H Mayer; Barry S Zingman
Journal:  AIDS Behav       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.